+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Triazolam improves sleep but fails to alter pain in TMD patients

Triazolam improves sleep but fails to alter pain in TMD patients

Journal of Orofacial Pain 12(2): 116-123

Patients with chronic orofacial pain often report disturbances in sleep, leading to the hypothesis that nocturnal motor hyperactivity of the muscles of mastication may contribute to the nociceptive process. This hypothesis was tested in a controlled study to evaluate the relationship between sleep stages, patient self-report of pain in the orofacial region, and nocturnal masticatory muscle activity. Twenty subjects participating in a two-period, within-subject, crossover study received triazolam or placebo for 4 nights. Sleep, pain, and mandibular range of motion were assessed at baseline, following the first period, and again following the second period; a 3-day washout period separated the two treatments. Subjective report of sleep quality was significantly improved following triazolam in comparison to placebo as measured by category scales for sleep quality, restfulness, and sleep compared to usual. The amount of time spent in stage-2 sleep was also significantly increased by triazolam. No improvement was seen in pain as measured by palpation with an algometer, in scales for sensory intensity and the affective component of pain, or in daily pain diaries. Mean facial muscle electromyographic activity for 30-second epochs averaged over the entire period of sleep did not reveal any differences in muscle activity across the three conditions. These data indicate that improvements in sleep quality and alterations in sleep architecture do not affect nocturnal facial muscle activity or subsequent pain report in temporomandibular patients, thereby failing to support the hypothesized relationship between sleep disturbances and chronic orofacial pain.

(PDF emailed within 1 workday: $29.90)

Accession: 009676064

Download citation: RISBibTeXText

PMID: 9656889

Related references

Ultralow Dose of Naloxone as an Adjuvant to Intrathecal Morphine Infusion Improves Perceived Quality of Sleep but Fails to Alter Persistent Pain: A Randomized, Double-blind, Controlled Study. Clinical Journal of Pain 31(11): 968-975, 2016

Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. International Clinical Psychopharmacology 9(4): 251-261, 1994

Triazolam fails to induce sleep in suprachiasmatic nucleus-lesioned rats. Neuroscience Letters 125(2): 125-128, 1991

Triazolam impairs learning and fails to improve sleep in a long-range aerial deployment. Aviation, Space, and Environmental Medicine 60(6): 594-598, 1989

Triazolam as a hypnotic for geriatric patients. A double-blind cross-over comparison of nitrazepam and triazolam regarding effects on sleep and psychomotor performance. Acta Psychiatrica Scandinavica 67(5): 290-296, 1983

Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep 15(3): 212-216, 1992

Effects of zopiclone, flunitrazepam, triazolam and levomepromazine on the triazolam and levomepromazine on the transient change in sleep-wake schedule: Polygraphic study, and the evaluation of sleep and daytime condition. Progress in Neuro-Psychopharmacology & Biological Psychiatry 17(2): 229-239, 1993

Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials. Pain Practice 16(3): 345-358, 2016

Endorphins: naloxone fails to alter experimental pain or mood in humans. Science 199(4333): 1093-1095, 1978

Triazolam diminishes daytime sleepiness and sleep fragmentation in patients with periodic leg movements in sleep. Journal of Clinical Psychopharmacology 11(5): 284-290, 1991

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. Journal of Clinical Investigation 89(5): 1551-1557, 1992

Triazolam in patients with obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine 151(2 Pt 1): 450-454, 1995

Sleep disorder in hemodialysis patients the efficacy and effects of triazolam. Kidney International 35(1): 252, 1989

Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 54(10): 1402-1407, 2005

Pregabalin Reduces Pain and Improves Sleep and Mood Disturbances in Patients with Postherpetic Neuralgia Results of a Randomized, Placebo-Controlled Clinical Trial. Anesthesiology Abstracts of Scientific Papers Annual Meeting ( ): Abstract No A-970, 2003